444 related articles for article (PubMed ID: 28933243)
1. Drug targets in dormant Mycobacterium tuberculosis: can the conquest against tuberculosis become a reality?
Gupta VK; Kumar MM; Singh D; Bisht D; Sharma S
Infect Dis (Lond); 2018 Feb; 50(2):81-94. PubMed ID: 28933243
[TBL] [Abstract][Full Text] [Related]
2. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
3. Persistent and dormant tubercle bacilli and latent tuberculosis.
Zhang Y
Front Biosci; 2004 May; 9():1136-56. PubMed ID: 14977534
[TBL] [Abstract][Full Text] [Related]
4. New 1-hydroxy-2-thiopyridine derivatives active against both replicating and dormant Mycobacterium tuberculosis.
Salina EG; Ryabova O; Vocat A; Nikonenko B; Cole ST; Makarov V
J Infect Chemother; 2017 Nov; 23(11):794-797. PubMed ID: 28527650
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel lysine ɛ-aminotransferase inhibitors: An intriguing potential target for latent tuberculosis.
Devi PB; Sridevi JP; Kakan SS; Saxena S; Jeankumar VU; Soni V; Anantaraju HS; Yogeeswari P; Sriram D
Tuberculosis (Edinb); 2015 Dec; 95(6):786-794. PubMed ID: 26299907
[TBL] [Abstract][Full Text] [Related]
6. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
7. The significance of persisters in tuberculosis drug discovery: Exploring the potential of targeting the glyoxylate shunt pathway.
Negi A; Sharma R
Eur J Med Chem; 2024 Feb; 265():116058. PubMed ID: 38128237
[TBL] [Abstract][Full Text] [Related]
8. Modeling of Mycobacterium tuberculosis dormancy in bacterial cultures.
Batyrshina YR; Schwartz YS
Tuberculosis (Edinb); 2019 Jul; 117():7-17. PubMed ID: 31378272
[TBL] [Abstract][Full Text] [Related]
9. Marine Natural Products and Drug Resistance in Latent Tuberculosis.
Khan MT; Kaushik AC; Bhatti AI; Zhang YJ; Zhang S; Wei AJ; Malik SI; Wei DQ
Mar Drugs; 2019 Sep; 17(10):. PubMed ID: 31561525
[TBL] [Abstract][Full Text] [Related]
10. Computational investigation of phytomolecules as resuscitation-promoting factor B (RpfB) inhibitors for clinical suppression of Mycobacterium tuberculosis dormancy reactivation.
Dwivedi VD; Arya A; Sharma T; Sharma S; Patil SA; Gupta VK
Infect Genet Evol; 2020 Sep; 83():104356. PubMed ID: 32438079
[TBL] [Abstract][Full Text] [Related]
11. Deletion of
Khan MZ; Nandicoori VK
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468473
[TBL] [Abstract][Full Text] [Related]
12. Small-Molecule Probes Reveal Esterases with Persistent Activity in Dormant and Reactivating Mycobacterium tuberculosis.
Tallman KR; Levine SR; Beatty KE
ACS Infect Dis; 2016 Dec; 2(12):936-944. PubMed ID: 27690385
[TBL] [Abstract][Full Text] [Related]
13. Controlling strategy of dormant Mycobacterium tuberculosis.
Gan Y; Guo S
Chin Med J (Engl); 2014; 127(18):3316-21. PubMed ID: 25266533
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
[TBL] [Abstract][Full Text] [Related]
15. Delamanid Kills Dormant Mycobacteria
Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
[TBL] [Abstract][Full Text] [Related]
16. Drug resistance mechanisms and novel drug targets for tuberculosis therapy.
Islam MM; Hameed HMA; Mugweru J; Chhotaray C; Wang C; Tan Y; Liu J; Li X; Tan S; Ojima I; Yew WW; Nuermberger E; Lamichhane G; Zhang T
J Genet Genomics; 2017 Jan; 44(1):21-37. PubMed ID: 28117224
[TBL] [Abstract][Full Text] [Related]
17. A mathematical representation of the development of Mycobacterium tuberculosis active, latent and dormant stages.
Magombedze G; Mulder N
J Theor Biol; 2012 Jan; 292():44-59. PubMed ID: 21968442
[TBL] [Abstract][Full Text] [Related]
18. A whole genome bioinformatic approach to determine potential latent phase specific targets in Mycobacterium tuberculosis.
Defelipe LA; Do Porto DF; Pereira Ramos PI; Nicolás MF; Sosa E; Radusky L; Lanzarotti E; Turjanski AG; Marti MA
Tuberculosis (Edinb); 2016 Mar; 97():181-92. PubMed ID: 26791267
[TBL] [Abstract][Full Text] [Related]
19. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
Kiran D; Podell BK; Chambers M; Basaraba RJ
Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
[TBL] [Abstract][Full Text] [Related]
20. A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen.
Deb C; Lee CM; Dubey VS; Daniel J; Abomoelak B; Sirakova TD; Pawar S; Rogers L; Kolattukudy PE
PLoS One; 2009 Jun; 4(6):e6077. PubMed ID: 19562030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
